OVERVIEW

Diabetes Consultations™: Beyond Insulin: The Role of SGLT-2 Inhibitors in Care of Patients with T1DM is organized by Physicians' Education Resource, LLC (PER).

Release Date: July 31, 2019
Expiration Date: July 31, 2020

Target Audience:
This activity is intended for community endocrinologists, diabetologists, primary care clinicians, nurse practitioners, physician assistants, certified diabetes educators, and nurses involved in the treatment and management of patients with type 1 diabetes (T1D). This activity will provide education to a broad multidisciplinary team who will be invited to participate.

Accreditation/Credit Designation:
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Activity Overview:
Type 1 diabetes (T1D) has an extensive global presence and affects over 1.25 million Americans who live with the daily challenges of appropriate insulin dosing and glucose monitoring. Less than one-third of patients properly manage their diabetes and blood glucose levels and nearly half are either obese or overweight. However, escalating insulin doses carries many risks, including hypoglycemia and weight gain. Newer classes of antihyperglycemic agents used in type 2 diabetes offer a potential clinical option to effectively reach glycemic targets in patients with T1D. However, knowledge and competency among clinicians on risks and benefits, patient selection, and education on the use of SGLT-2 inhibitors as adjunctive therapy are crucial for effective clinical decision making and improving patient outcomes. Perspectives from an endocrinologist involved in clinical trials of these agents and a primary care physician with a diabetes center in their practice will offer learners well-rounded perspectives on best practices for optimizing treatment plans for patients with T1D.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Identify patients with T1D who are not achieving their glycemic goals and who could benefit from adjunctive therapy to insulin
• Examine new and emerging data on SGLT1/2 inhibitors for potential adjunctive therapy for T1D
• Analyze risks and benefits associated with SLGT-2 inhibitor use in T1D
• Incorporate shared decision making to individualize therapy and improve patient outcomes in T1D.